JP2018516935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516935A5 JP2018516935A5 JP2017562758A JP2017562758A JP2018516935A5 JP 2018516935 A5 JP2018516935 A5 JP 2018516935A5 JP 2017562758 A JP2017562758 A JP 2017562758A JP 2017562758 A JP2017562758 A JP 2017562758A JP 2018516935 A5 JP2018516935 A5 JP 2018516935A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- lymphoma
- acceptable salt
- cell
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- -1 1- (but-2-ynoyl) piperidin-3-yl Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical group OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 208000007465 Giant cell arteritis Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 206010043207 temporal arteritis Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- KOEUOFPEZFUWRF-LJQANCHMSA-N 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one Chemical compound C(C=C)(=O)N1C[C@@H](CCC1)N1C(N(C=2C(=NC=CC=21)N)C1=CC=C(C=C1)OC1=CC=CC=C1)=O KOEUOFPEZFUWRF-LJQANCHMSA-N 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- FPGGLMIYNLQOID-UHFFFAOYSA-N 3h-pyridin-2-one Chemical compound O=C1CC=CC=N1 FPGGLMIYNLQOID-UHFFFAOYSA-N 0.000 claims 1
- YMALYAHRSSETHN-IBGZPJMESA-N 4-amino-3-(4-phenoxyphenyl)-1-[[(2S)-1-prop-2-enoylpyrrolidin-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound C(C=C)(=O)N1[C@@H](CCC1)CN1C(N(C=2C(=NC=CC=21)N)C1=CC=C(C=C1)OC1=CC=CC=C1)=O YMALYAHRSSETHN-IBGZPJMESA-N 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 210000000467 autonomic pathway Anatomy 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 125000004476 heterocycloamino group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020001139A JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170547P | 2015-06-03 | 2015-06-03 | |
| US62/170,547 | 2015-06-03 | ||
| US201562271689P | 2015-12-28 | 2015-12-28 | |
| US62/271,689 | 2015-12-28 | ||
| PCT/US2016/035588 WO2016196840A1 (en) | 2015-06-03 | 2016-06-02 | Tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001139A Division JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516935A JP2018516935A (ja) | 2018-06-28 |
| JP2018516935A5 true JP2018516935A5 (enExample) | 2019-06-27 |
| JP6646072B2 JP6646072B2 (ja) | 2020-02-14 |
Family
ID=56118090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562758A Active JP6646072B2 (ja) | 2015-06-03 | 2016-06-02 | チロシンキナーゼ阻害剤 |
| JP2020001139A Active JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001139A Active JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Country Status (33)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150044271A1 (en) | 2012-02-27 | 2015-02-12 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
| RS58956B1 (sr) | 2012-09-10 | 2019-08-30 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| CN105764814B (zh) | 2013-11-29 | 2019-02-19 | 株式会社大造 | 内容物收容容器、使用其的内容物收容制品、排出制品及排出装置 |
| EA033900B1 (ru) | 2014-02-21 | 2019-12-06 | Принсипиа Биофарма Инк. | СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ |
| CA2970723C (en) | 2014-12-18 | 2023-09-05 | Principia Biopharma Inc. | Treatment of pemphigus |
| KR102666352B1 (ko) * | 2015-06-03 | 2024-05-17 | 프린시피아 바이오파마, 인코퍼레이티드 | 티로신 키나제 억제제 |
| EP3313839A1 (en) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| CA3008653A1 (en) * | 2015-10-14 | 2017-04-20 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| SG11201811255WA (en) | 2016-06-29 | 2019-01-30 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| JP6920411B2 (ja) * | 2016-07-25 | 2021-08-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ |
| WO2018156901A1 (en) * | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP3789040A4 (en) * | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| CA3224945C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| KR102830577B1 (ko) * | 2018-09-13 | 2025-07-08 | 깃세이 야쿠힌 고교 가부시키가이샤 | 이미다조피리디논 화합물 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| CN115209899A (zh) | 2019-10-14 | 2022-10-18 | 普林斯匹亚生物制药公司 | 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| CN113045484B (zh) * | 2019-12-27 | 2024-01-26 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法 |
| CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法 |
| TWI883107B (zh) | 2020-01-20 | 2025-05-11 | 美商普林斯匹亞生物製藥公司 | 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑 |
| MX2022009009A (es) | 2020-01-22 | 2022-08-15 | Principia Biopharma Inc | Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115397427A (zh) * | 2020-03-30 | 2022-11-25 | Igia制药有限公司 | 酪氨酸激酶抑制剂的儿科制剂 |
| CN115701997B (zh) * | 2020-08-10 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | Btk抑制剂治疗疾病的用途 |
| KR20230051227A (ko) | 2020-08-14 | 2023-04-17 | 노파르티스 아게 | 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도 |
| CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
| WO2022121670A1 (zh) | 2020-12-10 | 2022-06-16 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| CN116710452A (zh) * | 2020-12-23 | 2023-09-05 | 建新公司 | 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类 |
| AU2021409575A1 (en) * | 2020-12-23 | 2023-08-10 | Principia Biopharma Inc. | 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2022218430A1 (zh) * | 2021-04-16 | 2022-10-20 | 南京明德新药研发有限公司 | 咪唑并吡啶类化合物及其应用 |
| CN117295735A (zh) | 2021-04-23 | 2023-12-26 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| CN117412749A (zh) * | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| IL309263A (en) | 2021-06-11 | 2024-02-01 | Genzyme Corp | Crystalline form of tolbrotinib, method of preparation and use thereof |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| EP4404937A4 (en) * | 2021-09-24 | 2025-10-15 | Chadwick Donaldson | DRY POWDER FOAMING FORMULATIONS FOR DRUG DELIVERY ACROSS THE MUCOSA |
| CA3241687A1 (en) | 2021-12-21 | 2023-06-29 | Tim Owens | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| EP4490156A1 (en) * | 2022-03-09 | 2025-01-15 | Teva Pharmaceuticals International GmbH | Solid state forms of tolebrutinib and of tolebrutinib salts |
| US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
| IL317645A (en) * | 2022-06-14 | 2025-02-01 | Principia Biopharma Inc | Methods for preparing tolbrutinib |
| KR20250025711A (ko) * | 2022-06-22 | 2025-02-24 | 프린시피아 바이오파마, 인코퍼레이티드 | 변형된 btk 저해제의 제조 방법 |
| WO2024006406A1 (en) | 2022-06-30 | 2024-01-04 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| AU2023361384A1 (en) | 2022-10-11 | 2025-05-22 | Principia Biopharma Inc. | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| CN118891260B (zh) * | 2022-11-07 | 2025-07-25 | 天津瑞程健达医药科技有限公司 | 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物 |
| TW202432128A (zh) | 2022-12-20 | 2024-08-16 | 美商健臻公司 | （Ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１Ｈ－咪唑並［４，５－ｃ］吡啶－２（３Ｈ）－酮之藥品調配物 |
| IL322398A (en) | 2023-02-01 | 2025-09-01 | Principia Biopharma Inc | Methods for diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid and spinal cord |
| US20250282777A1 (en) | 2024-03-06 | 2025-09-11 | Principia Biopharma Inc. | Methods of Making Tolebrutinib |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US7244744B2 (en) | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| AU2005284835A1 (en) * | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| WO2006086634A2 (en) * | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| AU2007257423B8 (en) | 2006-05-31 | 2012-02-16 | The Regents Of The University Of California | Purine analogs |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| DK2529622T3 (en) | 2006-09-22 | 2018-05-07 | Pharmacyclics Llc | INHIBITORS OF BRUTON-TYROSINKINASE |
| NZ598705A (en) | 2009-09-16 | 2014-06-27 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| TWI500617B (zh) * | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| BR112013029508B1 (pt) * | 2011-05-17 | 2022-05-03 | Principia Biopharma, Inc. | Composto, composição farmacêutica, e, uso do referido composto |
| WO2012158785A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| SI2710005T1 (sl) * | 2011-05-17 | 2017-03-31 | Principia Biopharma Inc. | Zaviralci tirozinske kinaze |
| DK2786996T3 (en) * | 2011-11-29 | 2016-12-19 | Ono Pharmaceutical Co | Hydrochloride PURINONDERIVAT |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| MX368112B (es) * | 2012-06-18 | 2019-09-18 | Principia Biopharma Inc | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| RS58956B1 (sr) * | 2012-09-10 | 2019-08-30 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| US20140142099A1 (en) * | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR102666352B1 (ko) * | 2015-06-03 | 2024-05-17 | 프린시피아 바이오파마, 인코퍼레이티드 | 티로신 키나제 억제제 |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| CA3008653A1 (en) | 2015-10-14 | 2017-04-20 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
-
2016
- 2016-06-02 KR KR1020227035399A patent/KR102666352B1/ko active Active
- 2016-06-02 TW TW105117466A patent/TWI732765B/zh active
- 2016-06-02 KR KR1020247015612A patent/KR20240070721A/ko active Pending
- 2016-06-02 TW TW110121130A patent/TWI810582B/zh active
- 2016-06-02 PH PH1/2017/502203A patent/PH12017502203B1/en unknown
- 2016-06-02 EP EP22188609.6A patent/EP4112618A1/en active Pending
- 2016-06-02 DK DK16728566.7T patent/DK3303334T3/da active
- 2016-06-02 CA CA2987335A patent/CA2987335A1/en active Pending
- 2016-06-02 US US15/578,623 patent/US20180162861A1/en not_active Abandoned
- 2016-06-02 JP JP2017562758A patent/JP6646072B2/ja active Active
- 2016-06-02 PH PH1/2021/551681A patent/PH12021551681A1/en unknown
- 2016-06-02 LT LTEPPCT/US2016/035588T patent/LT3303334T/lt unknown
- 2016-06-02 WO PCT/US2016/035588 patent/WO2016196840A1/en not_active Ceased
- 2016-06-02 HU HUE16728566A patent/HUE055419T2/hu unknown
- 2016-06-02 CR CR20170593A patent/CR20170593A/es unknown
- 2016-06-02 SI SI201631244T patent/SI3303334T1/sl unknown
- 2016-06-02 PT PT167285667T patent/PT3303334T/pt unknown
- 2016-06-02 ES ES16728566T patent/ES2878030T3/es active Active
- 2016-06-02 AU AU2016270973A patent/AU2016270973B2/en active Active
- 2016-06-02 EA EA201792529A patent/EA039006B1/ru unknown
- 2016-06-02 UA UAA201712794A patent/UA124090C2/uk unknown
- 2016-06-02 MX MX2021006571A patent/MX395007B/es unknown
- 2016-06-02 PE PE2017002512A patent/PE20180521A1/es unknown
- 2016-06-02 KR KR1020177037609A patent/KR102552653B1/ko active Active
- 2016-06-02 HR HRP20211249TT patent/HRP20211249T1/hr unknown
- 2016-06-02 MY MYPI2017704576A patent/MY190548A/en unknown
- 2016-06-02 PL PL16728566T patent/PL3303334T3/pl unknown
- 2016-06-02 EP EP16728566.7A patent/EP3303334B1/en active Active
- 2016-06-02 EP EP21169631.5A patent/EP3912979A1/en active Pending
- 2016-06-02 CN CN202011284728.3A patent/CN113149983B/zh active Active
- 2016-06-02 HK HK18111674.0A patent/HK1252378A1/zh unknown
- 2016-06-02 MX MX2017015470A patent/MX383213B/es unknown
- 2016-06-02 TN TNP/2017/000501A patent/TN2017000501A1/en unknown
- 2016-06-02 SG SG10201912443XA patent/SG10201912443XA/en unknown
- 2016-06-02 RS RS20211083A patent/RS62290B1/sr unknown
- 2016-06-02 CN CN201680000891.8A patent/CN106459049B/zh active Active
-
2017
- 2017-01-19 US US15/410,716 patent/US9688676B2/en active Active
- 2017-11-27 IL IL255946A patent/IL255946A/en active IP Right Grant
- 2017-12-01 CL CL2017003073A patent/CL2017003073A1/es unknown
- 2017-12-01 DO DO2017000279A patent/DOP2017000279A/es unknown
- 2017-12-15 CO CONC2017/0012947A patent/CO2017012947A2/es unknown
- 2017-12-19 ZA ZA2017/08667A patent/ZA201708667B/en unknown
-
2019
- 2019-07-31 CL CL2019002150A patent/CL2019002150A1/es unknown
-
2020
- 2020-01-08 JP JP2020001139A patent/JP6985433B2/ja active Active
- 2020-05-26 AU AU2020203447A patent/AU2020203447B2/en active Active
- 2020-09-23 US US17/029,184 patent/US20210171526A1/en not_active Abandoned
- 2020-12-07 IL IL279258A patent/IL279258B/en unknown
-
2022
- 2022-10-27 US US17/974,613 patent/US20230151012A1/en not_active Abandoned
-
2024
- 2024-02-13 ZA ZA2024/01324A patent/ZA202401324B/en unknown
- 2024-11-26 US US18/960,997 patent/US20250197402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516935A5 (enExample) | ||
| HRP20211249T1 (hr) | Inhibitori tirozin kinaze | |
| JP6776399B2 (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| AU2017383236B2 (en) | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | |
| KR102329162B1 (ko) | 카이네이즈 저해제로서의 피라졸로피리미딘 유도체 | |
| CA2900855C (en) | Aminopyrimidinyl compounds | |
| CN108602827B (zh) | Bruton酪氨酸激酶的咪唑并吡嗪抑制剂 | |
| US20160039802A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| JP2014506930A5 (enExample) | ||
| JP2010501003A5 (enExample) | ||
| JP2011520896A5 (enExample) | ||
| JP2016525135A5 (enExample) | ||
| BR112015023142B1 (pt) | Moduladores do p2x7, seu uso, processo de preparação e composição farmacêutica que os compreende | |
| CA2759160A1 (en) | 3-azabicyclo [4.1.0] heptanes used as orexin antagonists | |
| RU2013143839A (ru) | Ингибиторы сериновых/треониновых киназ | |
| JP2016530338A5 (enExample) | ||
| JP2014509647A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| WO2014147586A1 (en) | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh | |
| JP2020529419A5 (enExample) | ||
| JP2016535042A5 (enExample) | ||
| JP2015535851A5 (enExample) | ||
| CN114573586A (zh) | 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用 | |
| AU2018350980A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors | |
| JP2013523814A5 (enExample) |